Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
SANA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.52 - $10.50
Previous CloseN/A
Volume118.31M
Average Volume (3M)3.11M
Market Cap
$384.79M
Enterprise Value$872.56M
Total Cash (Recent Filing)$80.03M
Total Debt (Recent Filing)$48.21M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 13, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding225,024,900
10 Day Avg. Volume4,455,440
30 Day Avg. Volume3,114,834
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-28.27
Enterprise Value/Ebitda-3.03
Forecast
1Y Price Target
$9.50Price Target Upside455.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Clinical DataSana Biotechnology reported positive 12-week survival data for HIP-edited hypoimmune donor-derived pancreatic islet cells, showing no safety issues and evasion of immune detection.
Financial PositionThe company's cash position is strong with $152.5 million, suggesting financial stability and the ability to continue funding its research and development efforts.
Strategic DevelopmentsSana plans to submit an IND for an in-vivo CART program, which could be a significant development in B-cell driven autoimmune diseases and cancers.
Bears Say
Clinical LimitationsSome investors note that the C-peptide levels were significantly lower than normal levels and therefore not enough for the patients to achieve insulin independence.
Operational PerformanceThe report of no revenues and higher-than-expected R&D and SG&A expenses might raise concerns about Sana's current operational performance.
Revenue And ExpensesSana reported no revenues for 4Q24, with R&D and SG&A expenses higher than estimated.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.52 and its highest was $10.50 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $384.79M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is May 13, 2025 which is in 43 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Mar 17, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.036.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.24.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 225,024,900 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -17.69%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
---
Sana Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (455.56% Upside)
$9.50 (455.56% Upside)
Blogger Sentiment
Bullish
SANA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 115.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.90%
12-Months-Change
Fundamentals
Return on Equity
-99.17%
Trailing 12-Months
Asset Growth
-11.37%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
---
SANA Stock 12 Month Forecast
Average Price Target
$9.50
▲(455.56% Upside)
Technical Analysis
Arcturus Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering SANA
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-31.38%
reiterated a buy rating 3 months ago
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -31.38% per trade.
---